

June 2, 2014



CymaBay Therapeutics to Present at Upcoming Conferences

NEWARK, CA -- (Marketwired) -- 06/02/14 -- CymaBay Therapeutics, Inc.(OTCQB: CYMA), today announced that senior management will present an overview of the company at the following upcoming conferences.

Jefferies 2014 Global Healthcare Conference

Date: June 5, 2014

Location: Grand Hyatt New York

Presentation: 8:00am - 8:30am

2014 Wells Fargo Healthcare Conference

Date: June 18, 2014

Location: InterContinental Boston

Presentation: 1:50pm - 2:20pm

About CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough therapies to treat metabolic and rare diseases with high unmet need. Arhalofenate, the Company's lead product candidate, possesses two therapeutic actions in a single drug. In gout patients, arhalofenate is intended to prevent painful attacks in joints through an anti-inflammatory effect while at the same time promoting excretion of uric acid by the kidney, thereby addressing both the key debilitating symptom and the underlying cause of the disease. CymaBay is currently investigating arhalofenate in a 12-week Phase 2b clinical trial in patients with gout. The Company's second product candidate, MBX-8025, demonstrated favorable effects on cholesterol, triglycerides and markers of liver health in a Phase 2 clinical trial in patients with mixed dyslipidemia. MBX-8025 is currently being considered for further development in certain orphan diseases.

For additional information about CymaBay visit www.cymabay.com.

Contact:

Sujal Shah

CymaBay Therapeutics, Inc.

(510) 293-8800

investors@cymabay.com

or

Adam Cutler

The Trout Group, LLC

(646) 378-2936

CymaBay@troutgroup.com

Source: CymaBay Therapeutics